Ipsen, Servier Advance Lung Cancer Drug After Posting Encouraging Data
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.
You may also be interested in...
AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.
The US FDA has designated GE Healthcare’s recall of its CARESCAPE R860 ventilator as Class I, the agency’s most serious category.